CD274 and esophageal squamous cell carcinoma: Pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy is recommended for patients with ESCC with PD-L1 CPS ≥ 10 as first-line treatment (median OS 13.5 months) [27].